AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ross, G. H.
Right arrow Articles by Rotschafer, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ross, G. H.
Right arrow Articles by Rotschafer, J. C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2001, p. 2136-2140, Vol. 45, No. 7
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.7.2136-2140.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Fluoroquinolone Resistance in Anaerobic Bacteria following Exposure to Levofloxacin, Trovafloxacin, and Sparfloxacin in an In Vitro Pharmacodynamic Model

Gigi H. Ross,1,2 David H. Wright,1,2 Laurie Baeker Hovde,2 Marnie L. Peterson,1,2 and John C. Rotschafer1,2,*

University of Minnesota, College of Pharmacy, Minneapolis, Minnesota, 55455,1 and Regions Hospital, Department of Clinical Pharmacy, St. Paul, Minnesota, 551012

Received 24 February 2000/Returned for modification 4 July 2000/Accepted 18 April 2001

This investigation explored pharmacodynamic characteristics of fluoroquinolones against Bacteroides thetaiotamicron and the potential for development of resistance. An in vitro model was used to generate kill curves with three fluoroquinolones at various area under the concentration-time curve (AUC)/MIC ratios. Concentration-independent killing was observed. Increases in MICs were noted following exposure to fluoroquinolones at AUC/MIC ratios of 6 to 14.

* Corresponding author. Mailing address: Department of Clinical Pharmacy, Regions Hospital, 640 Jackson St., St. Paul, MN 55101. Phone: (651) 221-3896. Fax: (651) 292-4031. E-mail: rotsc001{at}tc.umn.edu.

Antimicrobial Agents and Chemotherapy, July 2001, p. 2136-2140, Vol. 45, No. 7
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.7.2136-2140.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2001 by the American Society for Microbiology. All rights reserved.